Besides, atezolizumab is the first FDA-approved anti-PD-L1 drug currently prescribed for urothelial carcinomas and non-small cell lung cancer (NSCLC) (86, 88, 89). The gene discussed is CD274; the disease is non-small cell lung carcinoma.